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Spectrum of acute renal failure in the intensive care unit: The
PICARD experience.
Background. Acute renal failure (ARF) in the critically ill is
associated with extremely high mortality rates. Understanding
the changing spectrum of ARF will be necessary to facilitate
quality improvement efforts and to design successful interven-
tional trials.
Methods. We conducted an observational cohort study of 618
patients with ARF in intensive care units at five academic med-
ical centers in the United States. Participants were required
to sign (or have a proxy sign) informed consent for data col-
lection. A comprehensive data collection instrument captured
more than 800 variables, most on a daily basis, throughout the
course of ARF. Patient characteristics, dialysis status, and major
outcomes were determined and stratified by clinical site.
Results. The mean age was 59.5 years, 41% were women, and
20% were of minority race or ethnicity. There was extensive
comorbidity; 30% had chronic kidney disease, 37% had coro-
nary artery disease, 29% had diabetes mellitus, and 21% had
chronic liver disease. Acute renal failure was accompanied by
extrarenal organ system failure in most patients, even those who
did not require dialysis. Three hundred and ninety-eight (64%)
patients required dialysis. The in-hospital mortality rate was
37%, and the rate of mortality or nonrecovery of renal func-
tion was 50%. The median hospital length of stay was 25 days
(26 days, excluding patients who died).
Conclusion. There is a changing spectrum of ARF in the criti-
cally ill, characterized by a large burden of comorbid disease and
extensive extrarenal complications, obligating the need for dial-
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ysis in the majority of patients. There is wide variation across in-
stitutions in patient characteristics and practice patterns. These
differences highlight the need for additional multicenter obser-
vational and interventional studies in ARF.
Acute renal failure (ARF) in the critically ill has been
the topic of numerous reports over the past four decades.
Many of these reports have focused on the associated high
mortality rates; observational data from a broad range of
centers have suggested in-hospital mortality rates in ex-
cess of 50% in most reported series [1–10]. Identification
of risk factors, comparison of severity scores, and com-
parisons of nonrandomized treatment strategies (e.g.,
diuretic agents, dopamine, dialysis modality) have domi-
nated this literature [11–21].
Arguably most striking has been the lack of obvious
improvement in acute renal failure–associated mortality
rates over time. Such a dilemma would typically stim-
ulate clinical investigation, given vast potential for im-
provement. However, owing in part to wide variation in
patient characteristics, practice patterns, and outcomes
across centers and among published reports, even identi-
fying major areas for potential intervention has been dif-
ficult. While several randomized clinical trials have been
conducted in the more recent past [22–25], most have
shown no benefit.
In an effort to develop a large registry of critically ill
patients with ARF across multiple clinical sites, we cre-
ated the Program to Improve Care in Acute Renal Dis-
ease (PICARD). The major goal of PICARD was to
leverage the diversity of several sites and a relatively
large sample of patients to better understand those de-
mographic, process, renal, and nonrenal clinical factors
associated with favorable and unfavorable outcomes, in-
cluding mortality, nonrecovery of renal function, and re-
source utilization. In doing so, our hope was to provide a
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Table 1. Baseline characteristics of PICARD cohort on day of nephrology consultation
CCF MMC VU UCSD UCSF
Variable N All N = 170 N = 93 N = 103 N = 89 N = 163 P value
Mean age year 615 59.5 63.2 69.0 56.8 52.8 55.5 <.0001
% Male 618 59% 65% 70% 58% 49% 52% 0.006
Race/ethnicity <.0001
% Caucasian 493 79.9% 86% 99% 94% 53% 69%
% African American 51 8.3% 11% 1% 6% 8% 12%
% Hispanic 39 6.3% 1% 0% 0% 27% 8%
% Asian/Pacific Islander 25 4.1% 0% 0% 0% 11% 9%
% Other/mixed race 9 1.5% 2% 0% 0% 1% 2%
% CKD 579 30% 44% 30% 30% 19% 19% <.0001
% Surg pre/at ICU admission 610 38% 44% 51% 36% 29% 29% 0.002
% HTN 618 53% 65% 69% 42% 42% 43% <.0001
% DM 618 29% 32% 41% 25% 20% 26% 0.02
% COPD 618 16% 22% 17% 20% 6% 12% 0.003
% CHF 618 28% 52% 16% 24% 9% 21% <.0001
% CAD 618 37% 53% 51% 35% 11% 27% <.0001
% Leukemia 599 3% 3% 1% 1% 2% 6% 0.09
% Lymphoma 618 4% 4% 2% 6% 0% 7% 0.06
% Liver disease 618 21% 9% 5% 20% 40% 31% <.0001
% HIV positive 618 1% 0% 0% 1% 2% 1% 0.31
% Immunocopromised 618 12% 9% 5% 16% 4% 20% 0.0003
% Chemotherapy 618 9% 7% 6% 5% 3% 18% 0.0001
% Radiation therapy 618 6% 5% 6% 2% 4% 9% 0.23
% Steroid therapy 618 15% 11% 5% 17% 20% 21% 0.002
Mean Apache 3 score 536 86 79 82 87 96 90 <.0001
Mean Apache 2 score 532 20 18 19 19 22 22 <.0001
Mean # organ systems failed 550 2.9 2.3 3.3 2.8 2.9 3.2 <.0001
% CNS failure 551 20% 10% 33% 18% 40% 13% <.0001
% Renal failure 553 95% 91% 98% 92% 99% 97% 0.02
% Liver failure 550 31% 17% 20% 26% 43% 50% <.0001
% Hermatologic failure 553 25% 8% 20% 19% 10% 61% <. 0001
% Cardiovascular failure 553 48% 55% 81% 54% 19% 34% <.0001
% Respiratory failure 552 67% 53% 74% 71% 78% 69% 0.0003
Mean heart rate per min 594 95 90 90 102 98 97 <.0001
Mean systolic BP mm hg 596 115 114 118 113 115 116 0.56
Mean diastolic BP mm Hg 595 56 55 53 57 57 58 0.1
Mean mean arterial BP mm Hg 595 76 75 74 75 77 77 0.58
Mean pulse pressure mm Hg 595 59 58 65 56 58 59 0.02
Mean temp (deg ◦C) 593 37 36.8 37.0 36.9 37.0 37.2 0.06
Median UO ml 597 946 1264 1045 656 652 1010 0.006
% Oliguria ≤400 mL/day 597 29% 22% 14% 37% 42% 32% <.0001
Mean resporatory rate 597 20.1 18.8 17.0 22.1 20.9 21.4 <.0001
Mean AM weight kg 413 87.1 84.5 88.9 89.3 82.9 89.0 0.27
Median total bilirubin mg/dL 339 1.7 1.1 1.1 2.1 4.2 2.6 <.0001
Mean creatinine mg/dL 596 3.39 3.58 3.27 3.27 3.41 3.31 0.55
Mean BUN mg/dL 591 65 71 59 60 73 61 0.003
Mean platelets 1000/mm3 545 155 157 165 172 137 148 0.26
Mean pH 342 7.35 7.37 7.34 7.3 7.36 7.35 0.005
Mean potassium mEg/L 593 4.6 4.6 4.6 4.6 4.7 4.6 0.96
Mean bicarbonate mEg/L 589 21.4 21.7 22.9 22.6 20.7 19.7 <.0001
Mean leukocyte 1000/mm3 558 14.0 13.1 14.4 14.6 15.1 13.9 0.59
Mean hemoglobin g/dL 557 10.2 10.2 10.1 10.3 10.5 10.2 0.79
contemporary view of the disease process, and to identify
those areas most suitable for intervention.
In this manuscript, we describe the methods of pa-
tient selection and data acquisition, and the spectrum
of collected clinical and process variables. We also
report on major study outcomes, focusing on differ-
ences by clinical site, dialysis requirement, and etiol-
ogy of acute renal failure. We hypothesized that there
would be significant differences in patient character-
istics, processes of care, and outcomes across clinical
sites.
METHODS
Study participants
The PICARD network is comprised of five academic
medical centers in the United States [University of
California San Diego (UCSD) (Coordinating Center),
Cleveland Clinic Foundation (CCF), Maine Medical Cen-
ter (MMC), Vanderbilt University (VU), and University
of California San Francisco (UCSF)]. Over a 31-month
period (February 1999 to August 2001), all patients con-
sulted for ARF in the intensive care unit (ICU) were
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Fig. 1. The distribution of patients by dialysis status—no dialysis, IHD
only, CRRT only, IHD followed by CRRT, and CRRT followed by
IHD. Dialysis status × site, P < 0.0001. IHD, intermittent hemodialysis;
CRRT, continuous renal replacement therapy.
evaluated by PICARD study personnel for potential
study participation. Given the large number of ICU beds
at CCF, one in six ARF patients were randomized for
possible study inclusion, to avoid single center over-
representation. Acute renal failure was defined as an
increase in serum creatinine ≥0.5 mg/dL with baseline
serum creatinine <1.5 mg/dL (new onset ARF), or an
increase in serum creatinine ≥1.0 mg/dL with baseline
serum creatinine ≥1.5 mg/dL and <5.0 mg/dL [ARF on
chronic kidney disease (CKD)]. Patients with a base-
line serum creatinine ≥5.0 mg/dL were not considered
for study inclusion. Other exclusion criteria included age
<18 years, previous dialysis, kidney transplantation, ARF
from urinary tract obstruction and hypovolemia respon-
sive to fluids; prisoners and pregnant patients were also
excluded. Patients who were contacted by study person-
nel and who signed (or whose proxy signed) informed
consents were enrolled in the study cohort. The reason
for nonenrollment was determined for patients who did
not sign informed consent [26], although no additional
data were collected for privacy considerations. The Com-
mittees on Human Research at each participating clinical
site approved the study protocol and informed consent.
Data collection strategy
If the PICARD inclusion and exclusion criteria were
met and informed consent obtained, the ICU chart was
reviewed to determine on which hospital day the patient
met ARF criteria. Data from the first ICU day, the first
day on which ARF criteria were met, the day of consul-
tation, and the three days preceding consultation were
obtained (in some instances, these days overlapped, but
were appropriately coded in the database to facilitate
subsequent analyses). Following consultation, data were
collected prospectively until three days after the end of
consultation or ICU discharge, whichever came first. For
patients with extended ICU stays or prolonged dialysis
requirements, data were collected for up to 10 weeks af-
ter the day of consultation, or eight weeks after the start
of dialysis. Finally, data on vital status, recovery of re-
nal function, and ICU and hospital lengths of stay were
collected on the day of hospital discharge.
Data management strategy
A scannable form was developed for data capture and
entry using the Teleform Designer Module (Cardiff Soft-
ware, San Diego, CA, USA). The Teleform Designer
generated a unique internal form ID to identify individ-
ual forms. Each PICARD site was equipped with hard-
ware and software to print forms locally with unique
patient identifiers. Study coordinators completed the
forms, which were then scanned and recognized by
the Teleform Reader Module. Following editing and val-
idation of data by the Teleform Verifier Module, the data
were transferred directly into the Teleform database at
each site. Site computers were connected to the UCSD
Data Coordinating Center server via a virtual private net-
work on the Internet. Data from the Teleform database
were encrypted and transferred via the Internet to the
SQL server using a Microsoft Peer to Peer Transfer pro-
tocol (MS PPTP; Microsoft, Redmond, WA, USA) for
secure connections. The data were deidentified and sub-
jected to a variety of rules and checks to identify any er-
rors before ultimately being transferred to the PICARD
database created in Microsoft SQL 7.0 using the Mi-
crosoft Data Engine (Microsoft). Data were backed up
each night, and periodic audits were performed to estab-
lish the accuracy of data capture and transfer into the
database.
Data elements
Multiple data elements (>800 per patient) were col-
lected on each PICARD participant. Data elements in-
cluded: demographics, comorbid conditions, hospital and
ICU admission and discharge data, ICD-9 admission and
discharge diagnosis codes, presumed etiologies of ARF,
vital signs, urine output, volume status (including in-
take and output), surgical procedures, nonsurgical pro-
cedures (e.g., radiology, echocardiography, endoscopy),
blood and urine laboratory studies including microbi-
ology, medication use, and the use of parenteral and
enteral nutrition. Multiple generic and ARF-specific
severity scores were calculated based on the data ob-
tained above. Organ failure was defined using validated
published criteria [18]. Dialysis procedures were evalu-
ated in exquisite detail, including data on vascular access,
anticoagulation, blood and dialysate flow rates, hemofil-
tration solution and dialysate composition, ultrafiltration
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Table 2. Baseline characteristics by dialysis status (all sites)
Initial Initial
IHD then CRRT then
Not IHD CRRT crossover crossover
Variable dialyzed only only to CRRT to IHD P value
Mean age (years) 62.9 61.7 53.6 56.3 56.2 <.0001
%Male 61% 57% 58% 47% 64% 0.51
Race/ethnicity 0.03
Caucasian 37% 26% 22% 4% 11%
African American 47% 25% 16% 4% 8%
Hispanic 18% 23% 28% 15% 15%
Asian/Pacific Islander 16% 32% 28% 8% 16%
Other/mixed race 33% 33% 11% 11% 11%
% CKD 34% 38% 17% 34% 22% 0.001
% Surg pre/at ICU admission 43% 36% 31% 32% 39% 0.22
% HTN 60% 54% 41% 53% 46% 0.007
% DM 33% 29% 23% 28% 28% 0.44
% COPD 17% 17% 11% 25% 17% 0.35
% CHF 32% 24% 28% 31% 22% 0.36
% CAD 49% 36% 24% 28% 28% <.0001
% Leukemia 3% 1% 6% 0% 4% 0.08
% Lymphoma 3% 3% 8% 0% 7% 0.05
% Liver disease 14% 21% 28% 31% 22% 0.008
% HIV positive 1% 1% 0% 0% 1% 0.72
% Immunocompromised 10% 11% 15% 13% 13% 0.66
% Chemotherapy 8% 8% 13% 3% 10% 0.24
% Radiation therapy 5% 5% 7% 6% 4% 0.87
% Steroid therapy 11% 14% 19% 31% 14% 0.02
Mean Apache 3 score 77 84 99 82 92 <.0001
Mean Apache 2 score 16 17 21 20 21 <.0001
Mean # organ systems failed 2.6 2.7 3.5 3.2 2.9 <.0001
% CNS failure 15% 16% 33% 23% 97 0.001
% Renal failure 92% 97% 95% 95% 97% 0.30
% Liver failure 19% 29% 50% 50% 31% <.0001
% Homatologic failure 18% 21% 41% 32% 23% <.0001
% Cardiovascular failure 54% 44% 50% 36% 40% 0.11
% Respiratory failure 57% 60% 84% 68% 77% <.0001
Mean heart rate per min 93 90 102 89 99 <.0001
Mean systolic BP mm Hg 116 122 105 122 113 <.0001
Mean diastolic BP mm Hg 56 58 51 62 57 0.0003
Mean mean arterial BP mm Hg 76 79 69 82 76 <.0001
Mean pulse pressure mm Hg 60 64 54 60 55 .0003
Mean temp ◦C 37.0 36.8 37.1 36.9 36.9 0.32
Median UO mL/day 1643 465 669 967 467 <.0001
% Oliguria ≤400 mL 10% 42% 34% 34% 46% <.0001
Mean respiratory rate per min 19 20 21 20 21 0.09
Mean AM. weight kg 86 85 91 85 91 0.18
Median total bilirubin mg/dL 1.2 1.3 3.3 1.7 1.5 <.0001
Mean creatinine mg/dL 3.0 3.9 3.3 3.5 3.7 <.0001
Mean BUN mg/dL 59 69 68 75 65 0.03
Mean platelets 1000/mm3 162 163 126 159 170 0.02
Mean pH 7.37 7.33 7.36 7.33 7.34 0.08
Mean potassium mEq/L 4.47 4.77 4.60 4.70 4.68 0.03
Mean bicarbonate mEq/L 22.9 20.8 20.5 19.7 20.3 <.0001
Mean Leukocyte 1000/mm3 13.9 14.2 14.1 13.5 14.4 0.99
Mean hemoglobin g/dL 10.0 10.5 10.2 10.5 9.9 0.18
prescription and weight loss achieved, along with dialysis-
associated medications, transfusions, and complications.
Outcomes
In-hospital mortality was the primary outcome; we also
collected ICU mortality and 28-day mortality. Recovery
of renal function was defined as dialysis independence
for at least three days prior to discharge. We considered
the combined outcome of death or nonrecovery (dialysis
dependence) after ARF. Finally, we collected information
on hospital and ICU lengths of stay.
Dialysis and nondialysis care
Intermittent dialysis was performed using volumetri-
cally controlled, bicarbonate-based machines and syn-
thetic biocompatible hemodialyzers. The indications,
frequency, and duration of intermittent dialysis treatment
were individualized for each patient based on prevalent
practices at each clinical site. Continuous techniques in-
cluded continuous veno-venous hemofiltration (CVVH),
continuous veno-venous hemodialysis (CVVHD), and
continuous veno-venous hemodiafiltration (CVVHDF).
Operational characteristics for each modality were
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Fig. 2. In-hospital mortality by dialysis status. Mortality × dialysis sta-
tus, P < 0.0001; mortality × dialysis status × site, P < 0.0001.
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Fig. 3. In-hospital mortality by presumed acute renal failure (ARF)
etiology—ischemic acute tubular nephropathy (ATN), nephrotoxic
ARF, both, or other. Mortality by etiology, P = 0.71; mortality × etiol-
ogy × site, P = 0.81.
determined by the treating nephrologists at each clini-
cal site. There were no prespecified criteria for initiation
or withdrawal of dialysis or for any aspect of dialysis care.
Concurrent ICU care for each patient was determined by
the treating physicians in conjuction with nephrologists.
No interventions were instituted as part of the PICARD
study.
Statistical analysis
Continuous variables are expressed as mean ± stan-
dard deviation or median and interquartile range and
compared using analysis of variance (general linear mod-
els with adjustment for multiple comparisons) or the
Kruskal-Wallis test where appropriate. Categorical vari-
ables are expressed as proportions and compared with
the Cochran-Mantel-Haenszel v 2 test or Fisher exact test.
Two-tailed P values < 0.05 were considered significant.
Statistical analyses were conducted using SAS 8.2 (SAS
Insitute, Cary, NC, USA).
RESULTS
Baseline characteristics
There were 618 patients enrolled in PICARD. Demo-
graphic data were obtained on virtually all patients, as
were data on comorbid conditions and the presumed
etiology of ARF. Vital signs, urine output, and routine
laboratory studies were obtained on more than 95% of
patients. Data sufficient to calculate the Acute Physiol-
ogy and Chronic Health Evaluation (APACHE) III and
other severity of illness scores were available in 94% of
patients. Other laboratory studies, procedures, and other
data elements were similarly well captured, although less
widely available due to the nonroutine nature of the in-
formation. As hypothesized, there were significant differ-
ences in numerous baseline characteristics, processes of
care, and outcomes by site.
Table 1 shows an array of baseline data from the day of
consultation, stratified by clinical site. The mean age was
59.5 years, though varied widely across sites. The majority
of patients were white, with a modest fraction of African
American patients at four of five sites. There was a mod-
est fraction of Hispanic and Asian/Pacific Islander pa-
tients, although these were derived exclusively from the
two California sites. Comorbid conditions were common,
although specific comorbidities varied widely by site. Pa-
tients at CCF and MMC had more extensive cardiovascu-
lar comorbidities (hypertension, coronary artery disease,
and heart failure) owing in part to the older ARF popu-
lations served. In contrast, liver disease and immunosup-
pression were more common among patients at UCSD
and UCSF. Respiratory failure was common among ARF
patients at all sites. The distribution of other failed organ
systems differed significantly. There were surprisingly few
intersite differences in vital signs or body weight. The
median urine outputs were lowest and the fraction of
patients with oliguria highest at VU and UCSD. Mean
leukocyte counts were elevated, and hemoglobin concen-
trations were reduced, consistent with a high incidence of
infection and inflammation. The pH and bicarbonate con-
centrations were low, consistent with metabolic acidosis.
Aside from the total bilirubin concentration (correspond-
ing to the fraction of patients with acute and chronic liver
disease), there were relatively few differences across sites
in baseline laboratory data. Likewise, the distribution
of presumed etiologies of ARF was relatively uniform,
except for a lower fraction of patients with “prerenal”
azotemia at MMC, and a higher fraction of patients with
ARF associated with liver disease at UCSF.
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Table 3. Several recent studies of ARF in the ICU
% Mortality
Variable Ref. Year N Location No dialysis Dialysis
Brivet et al [3] 1996 360 Multicenter, France 43% 64%
Liano et al [6] 1998 748 Multicenter, Spain 53% 79%
De Mendonca et al [32] 2000 1411 16 countries, Eurpoe NA 44%
Silvester et al [7] 2001 299 Multicenter, Australia NA 47%
Metniz et al [33] 2002 839 Multicenter, Austria 39% 63%
Clermont et al [8] 2002 254 Pittsburgh, USA 23% 57%
Guerin et al [28] 2002 587 Multicenter, France NA 71%
Metcalfe et al [9] 2002 89 Multicenter, Scotland NA 74%
Mehta et al [18] 2002 605 Multicenter, California, USA 39% 61%
PICARD 2003 618 Multicenter, USA 24% 45%
Dialysis status
Three hundred and ninety-eight (64%) patients were
dialyzed for ARF. The overall utilization of continuous
renal replacement therapy (CRRT) was high, with 60%
of dialyzed patients receiving CRRT for all or part of
their dialysis course. Figure 1 shows the distribution of pa-
tients by dialysis modality [none, intermittent hemodialy-
sis (IHD) only, CRRT only, IHD followed by CRRT, and
CRRT followed by IHD] and stratified by site. Patients at
MMC (63%) and VU (70%) were more likely to undergo
IHD alone than patients at the other three sites (24% to
34%).
Table 2 shows the frequency of baseline charac-
teristics by dialysis status. Patients who did not re-
quire dialysis were more likely to have been hyperten-
sive with a history of coronary artery disease. Higher
urine output and lower APACHE III scores were also
associated with nondialysis-requiring ARF. The heart
rates were higher, and systolic, diastolic, and mean ar-
terial blood pressures lower among patients treated
with CRRT. Continuous therapy use was also associ-
ated with acute hepatic failure and the total bilirubin
concentration.
Mortality, mortality or nonrecovery, and lengths of stay
The overall in-hospital mortality rate was 37%
(231/618). The 28-day mortality rate was 22% (138/617;
the admission date was missing for one patient), and the
ICU mortality rate was 32% (199/618). Figure 2 shows
overall and site-specific in-hospital mortality by dialysis
status—no dialysis, IHD only, CRRT only, and combined
IHD + CRRT by initial dialysis modality. As expected, in-
hospital mortality rates were higher among patients who
required dialysis, particularly those selected for CRRT.
Patients with ARF superimposed on CKD had lower
mortality rates than those with new-onset ARF (31% vs.
41%, P = 0.03). Figure 3 shows overall and site-specific
in-hospital mortality rates by the presumed etiology of
ARF. For these analyses, mutually exclusive categories
were created—ischemic ATN, nephrotoxic ARF, both,
and other. There was no relation between presumed eti-
ology of ARF and in-hospital mortality. An expanded
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Fig. 4. Mortality or nonrecovery by dialysis status. Combination out-
come by dialysis status, P < 0.0001; combination outcome by dialysis
status × site, P < 0.0001.
description of the presumed etiology of ARF (allowing
more than one etiology per case) is shown in Table 4.
Figures 4 and 5 show the combined outcome of mortality
or nonrecovery by dialysis status and ARF etiology, re-
spectively. When considering the combined outcome of
mortality or nonrecovery compared with mortality alone,
the differences among dialysis modalities were attenu-
ated.
Mortality rates were related to the severity of ex-
trarenal disease. Figure 6 shows overall and site-specific
in-hospital mortality rates by the number of failed or-
gan systems (an additive sum of cardiovascular, hepatic,
hematologic, neurologic, renal, and respiratory failure).
Mortality rates exceeded 50% with four or more failed
organ systems. The median hospital length of stay was
25 days (26 days when excluding patients who died).
DISCUSSION
The PICARD cohort may be the most comprehen-
sive registry of critically ill patients with ARF assem-
bled to date. Nonetheless, the study could not have been
conceived or implemented without the prior work con-
ducted by many committed investigators over the past
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Table 4. Presumes etiologies of ARF
Presumed etiologies N % of Total
Ischemic (non-nephrotoxic) ATN
Acute tubular necrosis precipitant not 311 50%
necessarity specified
Sepsis 119 19%
Hypotension 123 20%
Renal artery thrombosis, stenosis, or trauma 6 1%
Aortic dissection or aneurysm repair 6 1%
Prolonged surgical clamping 5 1%
Vascular, unspedcified 8 1%
Cortical necrosis 2 <1%
Nephrotoxic ARF, associated with
Calcineurin inhibitors 19 3%
Over-the-counter medications 4 1%
Other prescription medications 8 1%
Chemotherapy 7 1%
Illicit drugs 1 <1%
Aminoglycosides 8 1%
Antibiotics 19 3%
Nonsteroidal antiinflammatory drugs 2 <1%
Radiocontrast 54 9%
Rhabdomyolysis 24 4%
Tumor lysis syndrome 5 1%
Combined nephrotoxic 8 1%
ARF with inflammatory, infectious,
or malignant disease
Disseminated intravascular coagulation 6 1%
Malignant hypertension 2 <1%
Glomerulonephritis 11 2%
Interstitial nephritis 6 1%
Pyelonephritis 1 <1%
Bacterial endocarditis 2 <1%
Atheroembolic disease 1 <1%
Multiple myeloma 3 <1%
Systemic lupus erythematosus 6 1%
Hemolytic uremic syndrome 6 1%
Thrombotic thrombocvtopenic purpura 3 <1%
Other vasculitis 1 <1%
HIV-associated nephropathy 1 <1%
Multiple myeloma 3 <1%
Other neoplasms 8 1%
Extrarenal infections 2 <1%
ARF due to cardiac disease, associated with
Myocardial infarction 14 2%
Congestive heart failure 55 9%
Valvular heart disease 9 1%
Cardiogenic shock 37 6%
Cardiorenal syndrome 8 1%
Tamponade 4 1%
ARF due to unresolved prerenal factors,
associated with
Hemorrhage 29 5%
Hypovolemia 42 7%
Anaphylaxis 1 <1%
Autonomic nervous system failure 5 1%
Nausea and vomiting 6 1%
Diarrhea 15 2%
ARF due to liver disease, associated with
Hepatorenal syndrome 39 6%
Cirrhosis 11 2%
Hepatitis 7 1%
Liver disease, unspecified 10 2%
ARF with urinary tract obstruction
Nephrolithiasis 2 <1%
Tumors 1 <1%
Prostate disease 1 <1%
Urinary tract obstruction, cause unspecified 4 1%
Multifactorial
Mixed ARF with no primary designation 40 6%
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Fig. 5. Mortality or nonrecovery by presumed acute renal failure
(ARF) etiology. Combination outcome by etiology, P = 0.25; combi-
nation outcome by etiology × site, P = 0.65.
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40 years. Indeed, the plight of critically ill patients with
ARF has been the subject of dozens of published reports,
some dating back to the 1960s. A brief review of several
of these reports highlights the changing spectrum of ARF
over time. Kleinknecht et al [27] published a case series
of 500 patients with ARF seen between 1966 and 1970.
Two hundred and twenty-one patients received “prophy-
lactic” hemodialysis to maintain the urea concentration
below 200 mg/dL (corresponding to a BUN <93 mg/dL).
Compared with 279 patients cared for in earlier years
(during which dialysis was initiated if the urea concen-
tration was >350 mg/dL (BUN >164 mg/dL) or because
of other severe electrolyte disturbances, patients treated
with prophylactic hemodialysis experienced fewer ure-
mic complications and had a significantly lower mortal-
ity rate. McCarthy [5] reported a “tale of two eras,” in
which he compared an institution’s experience during the
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late 1970s with the same institution’s experience during
the early 1990s. He found higher survival rates during
the latter era, despite having more complicated causes
of ARF. Data from Brivet et al [3], Liano et al [4, 6],
and others [15, 28–31] have also suggested that while
overall mortality rates associated with ARF have not
materially improved, the number and complexity of ex-
trarenal complications in patients with ARF has indeed
increased. Table 3 summarizes ARF-associated mortal-
ity rates derived from several more recently published
studies.
Data from PICARD suggest that the trend toward
more complicated ARF continues into the 21st century.
More than half of patients with ARF in the ICU require
dialysis, and a large fraction has significant hemodynamic
instability. Among the 134 patients who required dialysis
and were assigned to CRRT alone, the average mean ar-
terial blood pressure was below 70 mm Hg despite the use
of pressor agents. These same patients had, on average,
between three and four failed organ systems. Therefore,
despite crude mortality rates that have remained high, it
is reasonable to conclude that outcomes associated with
ARF in the critically ill have indeed improved, at least
marginally, in the recent past.
There are several limitations to the information pre-
sented here. First, PICARD included academic medi-
cal centers providing extensive tertiary care. Therefore,
we may have overestimated the associated comorbid-
ity and severity of illness relative to what would be ex-
pected across institutions providing mainly primary and
community-based care. Second, it is difficult to categorize
the presumed etiology of ARF by clinical criteria. Given
considerable overlap and potential misclassification, we
may have erred in not identifying etiology-specific differ-
ences in mortality or nonrecovery. More precise determi-
nations of the etiology of ARF, including biopsy, would be
desirable in future studies. Third, because patients were
identified after nephrology consultation, we did not as-
certain cases that might have “qualified” by ARF diagno-
sis criteria but were not deemed sick enough to require
consultation, or who were so sick that nephrology con-
sultation was considered irrelevant. The requirement that
participants or their proxies signed informed consent was
associated with a large fraction of potential cases not be-
ing enrolled [26]. While detailed data were not available
on nonenrolled patients, many were not enrolled because
they expired before informed consent could be obtained.
In other words, patients who were healthy enough to sign
informed consent (or who had attendant family mem-
bers or friends) were likely to be different than “all com-
ers” with ARF in the ICU. Therefore, PICARD may
have underestimated ARF-associated mortality rates at
the participating institutions. Finally, we demonstrated
wide variation across sites, and the number of sites was
relatively small. Incorporating additional sites in future
efforts should provide an even clearer picture of contem-
porary ARF in the ICU.
CONCLUSION
ARF in the critically ill remains an extremely impor-
tant problem facing nephrologists and other intensivists.
The proportion of patients requiring dialysis is high; in-
stitutions with continuous dialysis capability appear to be
using these techniques with increasing frequency. There is
a considerable burden of extrarenal disease affecting pa-
tients before or concurrent with the ARF episode. There
is wide variation across institutions in patient characteris-
tics and practice patterns. These differences highlight the
need for additional multicenter observational and inter-
ventional studies in ARF.
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